COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) is providing an update on the status of the Oxycyte® Phase IIb protocol that has been submitted to the FDA. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier.
